Title : Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Pub. Date : 2014 Jun

PMID : 24468885






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Therefore, we designed a study using simvastatin/cetuximab/irinotecan for KRAS mutant CRC patients who are refractory to irinotecan and oxaliplatin-based chemotherapy. Oxaliplatin KRAS proto-oncogene, GTPase Homo sapiens